Geron is working to change the course of hematologic malignancies
Geron is a late-stage biopharmaceutical company with a mission to extend and enhance the lives of patients living with hematologic malignancies. Our first-in-class telomerase inhibitor, imetelstat, has demonstrated strong evidence of disease modification in Phase 2 trials.
Geron is focused on the development and potential commercialization of imetelstat and currently has two Phase 3 clinical trials ongoing: IMerge in lower risk myelodysplastic syndromes (LR MDS) and IMpactMF in relapsed/refractory myelofibrosis (MF). These indications represent potential multi-billion-dollar market opportunities. We have an experienced and knowledgeable management team and employee base to execute and deliver on our mission.